April 17, 2025

We Want Your Perspective!

Join our roster of respected specialists and share your clinical perspectives.

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 15, 2025

CT Exam Cancer Risk: Over 100,000 Cases Per Year

"At current utilization and radiation dose levels, CT examinations in 2023 were projected to result in approximately 103,000 future cancers," warns a new study that could reshape imaging practices.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

July 14, 2023

Scientists Discover a Deadly Brain Cancer’s Hidden Weakness

The difficult-to-treat brain cancer glioblastoma steals a person’s mental faculties as it spreads, yet the tumor’s insidious ability to infiltrate distant networks in the brain could also prove its undoing.

UCSF MedConnection

November 02, 2023

Immune Checkpoint Inhibition With Single-Fraction Stereotactic Radiosurgery May Not Increase Risk of Radiation Necrosis in Patients With NSCLC Brain Metastases

Researchers have explored the impact of a combination therapy on radiation necrosis in patients with non–small cell lung cancer (NSCLC) brain metastases.

The ASCO Post

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

July 26, 2024

EHR Use Disparities: Female vs. Male Surgeons

A recent study published in JAMA Network Open reveals gender differences in electronic health record (EHR) usage among surgeons, with female surgeons writing significantly longer progress notes than their male counterparts.

Conexiant

August 07, 2024

FDA Approves Voranigo for Grade 2 IDH-Mutant Glioma

The FDA's approval of voranigo marks a significant milestone as it becomes the first drug approved in the U.S. for the treatment of Grade 2 IDH-mutant glioma, a type of brain tumor, with promising results in a late-stage clinical trial.

Reuters